EMA/273414/2015 
Statement indicating compliance with the agreed completed 
paediatric investigation plan  
10 April 2015 
Medicinal product  
Orfadin 
nitisinone 
Pharmaceutical form(s): 
See Annex A of the CHMP Opinion 
Strength(s): 
See Annex A 
Route(s) of administration: 
See Annex A 
Packaging and package size(s):  See Annex A 
Number(s)in the Community 
See Annex A 
Register of Medicinal Products: 
Marketing Authorisation Holder (MAH): 
Name and address of the MAH:  Swedish Orphan Biovitrum International AB 
SE-112 76 Stockholm  
Sweden 
Procedure  
Procedure number: 
EMEA/H/C/000555/X/0041 
Further to the compliance check performed under Article 23 of Regulation EC (No° 1901/2006, and in 
accordance with Article 28(3) and Article 45(3) of the said Regulation it is concluded that: 
- the development of this product has complied with all measures in the agreed paediatric investigation 
plan P/0065/2012. For the purpose of the application of Article 45(3) of Regulation EC (No° 1901/2006, 
all studies in the agreed paediatric investigation plan P/0065/2012 were completed after the entry into 
force of that Regulation,-the Summary of Product Characteristics reflects the results of studies 
conducted in compliance with this agreed paediatric investigation plan.  
30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom 
Telephone  +44 (0)20 3660 6000  Facsimile +44 (0)20 3660 5555 
Send a question via our website www.ema.europa.eu/contact 
An agency of the European Union   
© European Medicines Agency, 2015. Reproduction is authorised provided the source is acknowledged. 
 
 
  
 
 
 
 
 
 
 
